tetano
Editor, Senior Moderator
mBio
. 2023 Dec 6:e0247723.
doi: 10.1128/mbio.02477-23. Online ahead of print. An in vitro experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody
Kristina E Atanasoff[SUP] 1 2 [/SUP], Luca Brambilla[SUP] 1 2 [/SUP], Daniel C Adelsberg[SUP] 1 [/SUP], Shreyas Kowdle[SUP] 1 [/SUP], Christian S Stevens[SUP] 1 2 [/SUP], Stefan Slamanig[SUP] 1 3 [/SUP], Chuan-Tien Hung[SUP] 1 [/SUP], Yanwen Fu[SUP] 4 [/SUP], Reyna Lim[SUP] 4 [/SUP], Linh Tran[SUP] 4 [/SUP], Robert Allen[SUP] 4 [/SUP], Weina Sun[SUP] 1 [/SUP], J Andrew Duty[SUP] 1 5 [/SUP], Goran Bajic[SUP] 1 [/SUP], Benhur Lee[SUP] 1 [/SUP], Domenico Tortorella[SUP] 1 [/SUP]
Affiliations
The COVID-19 pandemic remains a significant public health concern for the global population; the development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) variants emerge. Neutralizing monoclonal antibodies remain an effective therapeutic strategy to prevent virus infection and spread so long as they recognize and interact with circulating variants. The epitope and binding specificity of a neutralizing anti-SARS-CoV-2 Spike receptor-binding domain antibody clone against many SARS-CoV-2 variants of concern were characterized by generating antibody-resistant virions coupled with cryo-EM structural analysis and VSV-spike neutralization studies. This workflow can serve to predict the efficacy of antibody therapeutics against emerging variants and inform the design of therapeutics and vaccines.
Keywords: SARS-CoV-2; cryo-EM; epitope mapping; neutralizing antibody; structural analysis; viral resistance.
. 2023 Dec 6:e0247723.
doi: 10.1128/mbio.02477-23. Online ahead of print. An in vitro experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody
Kristina E Atanasoff[SUP] 1 2 [/SUP], Luca Brambilla[SUP] 1 2 [/SUP], Daniel C Adelsberg[SUP] 1 [/SUP], Shreyas Kowdle[SUP] 1 [/SUP], Christian S Stevens[SUP] 1 2 [/SUP], Stefan Slamanig[SUP] 1 3 [/SUP], Chuan-Tien Hung[SUP] 1 [/SUP], Yanwen Fu[SUP] 4 [/SUP], Reyna Lim[SUP] 4 [/SUP], Linh Tran[SUP] 4 [/SUP], Robert Allen[SUP] 4 [/SUP], Weina Sun[SUP] 1 [/SUP], J Andrew Duty[SUP] 1 5 [/SUP], Goran Bajic[SUP] 1 [/SUP], Benhur Lee[SUP] 1 [/SUP], Domenico Tortorella[SUP] 1 [/SUP]
Affiliations
- PMID: 38054729
- DOI: 10.1128/mbio.02477-23
The COVID-19 pandemic remains a significant public health concern for the global population; the development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) variants emerge. Neutralizing monoclonal antibodies remain an effective therapeutic strategy to prevent virus infection and spread so long as they recognize and interact with circulating variants. The epitope and binding specificity of a neutralizing anti-SARS-CoV-2 Spike receptor-binding domain antibody clone against many SARS-CoV-2 variants of concern were characterized by generating antibody-resistant virions coupled with cryo-EM structural analysis and VSV-spike neutralization studies. This workflow can serve to predict the efficacy of antibody therapeutics against emerging variants and inform the design of therapeutics and vaccines.
Keywords: SARS-CoV-2; cryo-EM; epitope mapping; neutralizing antibody; structural analysis; viral resistance.